Jinna E. Miller v. Abbott Laboratories

CourtDistrict Court, C.D. California
DecidedApril 3, 2023
Docket2:22-cv-05133
StatusUnknown

This text of Jinna E. Miller v. Abbott Laboratories (Jinna E. Miller v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jinna E. Miller v. Abbott Laboratories, (C.D. Cal. 2023).

Opinion

1 2 3 UNITED STATES DISTRICT COURT 4 CENTRAL DISTRICT OF CALIFORNIA 5 6 JULIAN FISHER as brought through his Case No. 2:22-cv-05133-SB (ASx) Conservator Jinna Miller 7 Plaintiff, 8 PROTECTIVE ORDER v. 9 ABBOTT LABORATORIES and 10 ABBVIE INC. 11 Defendants. 12 1. A. PURPOSES AND LIMITATIONS 13 14 Discovery in this action is likely to involve production of confidential, 15 proprietary, or private information for which special protection from public 16 disclosure and from use for any purpose other than prosecuting this litigation may 17 be warranted. Accordingly, the parties hereby stipulate to and petition the Court to 18 enter the following Stipulated Protective Order. The parties acknowledge that this 19 Order does not confer blanket protections on all disclosures or responses to 20 discovery and that the protection it affords from public disclosure and use extends 21 only to the limited information or items that are entitled to confidential treatment 22 under the applicable legal principles. The parties further acknowledge, as set forth 23 in Section 12.3, below, that this Stipulated Protective Order does not entitle them to 24 file confidential information under seal; Civil Local Rule 79-5 sets forth the 25 procedures that must be followed and the standards that will be applied when a party 26 seeks permission from the court to file material under seal. 27 1 B. GOOD CAUSE STATEMENT 2 This action is likely to involve the production of “Confidential Information” 3 for which special protection from public disclosure and from use for any purpose 4 other than prosecution of this action is warranted. Confidential Information is 5 defined herein to include information that is not in the public domain and contains 6 employee information, financial data and information, and any other information 7 that may reasonably be characterized by a party as intellectual property, a trade 8 secret, or confidential and proprietary information, including information protected 9 from disclosure by FDA regulations including 21 C.F.R.§ 20.63 and 21 C.F.R. § 10 314.430; information provided to Defendants Abbott Laboratories and AbbVie Inc. 11 (collectively, “Defendants”) by third parties with the expectation that Defendants 12 would keep such information confidential or pursuant to contracts that expressly 13 require Defendants to maintain the confidentiality of the information or that is 14 otherwise protected from disclosure by statute; names and other identifying 15 information of patients in clinical studies or adverse event reports as well as the 16 physicians who reported to Defendants adverse events concerning one of their 17 patients; confidential client lists; information that is not generally available to the 18 public that relates to, reflects or was or is used to help form Defendants’ research, 19 business and legal strategies, such as information that is not generally available to 20 the public that relates to, reflects or was or is used to help form Defendants’ research, 21 business and legal strategies, such as business or marketing plans or studies; sales 22 data that is kept confidential; pricing and financial information; discount 23 information; rebate information; plaintiff medical records and personal financial 24 information; non-public financial data that would reveal Defendants’ future strategic 25 commitments; information relating to job performance evaluations or disciplinary 26 actions; information that is not generally available to the public that relates to 27 consumer purchasing habits, pricing information, sales techniques, sales volumes; 1 and information concerning communication with government agencies. For 2 purposes of discovery, “trade secret” shall include any formula, compilation, 3 program, plan, device, design, method, technique, process or other information used 4 in the Producing Party’s business and for which confidentiality or sensitivity has 5 been reasonably maintained; and “proprietary” information shall mean any 6 information in which a party has a protectable interest, including information 7 regarding a party’s finances, processes, products, services, research and 8 development, sales and marketing, strategies and technologies, trade secret or other 9 confidential research, development or commercial information or other non-public 10 information about the financial and business affairs of the parties. 11 2. DEFINITIONS 12 2.1 Action: JULIAN FISHER as brought through his Conservator JINNA 13 MILLER v. ABBOTT LABORATORIES, et al., No. 2:22-cv-05133-SB 14 (ASx) 15 2.2 Challenging Party: a Party or Non-Party that challenges the designation 16 of information or items under this Order. 17 2.3 “CONFIDENTIAL” Information or Items: information (regardless of 18 how it is generated, stored or maintained) or tangible things that qualify 19 for protection under Federal Rule of Civil Procedure 26(c), and as 20 specified above in the Good Cause Statement. 21 2.4 Counsel: Outside Counsel of Record and House Counsel (as well as 22 their support staff). 23 2.5 Designating Party: a Party or Non-Party that designates information or 24 items that it produces in disclosures or in responses to discovery as 25 “CONFIDENTIAL.” 26 2.6 Disclosure or Discovery Material: all items or information, regardless 27 of the medium or manner in which it is generated, stored, or maintained 1 (including, among other things, testimony, transcripts, and tangible 2 things), that are produced or generated in disclosures or responses to 3 discovery in this matter. 4 2.7 Expert: a person with specialized knowledge or experience in a matter 5 pertinent to the litigation who has been retained by a Party or its 6 counsel to serve as an expert witness or as a consultant in this Action. 7 2.8 House Counsel: attorneys who are employees of a party to this Action. 8 House Counsel does not include Outside Counsel of Record or any 9 other outside counsel. 10 2.9 Non-Party: any natural person, partnership, corporation, association, or 11 other legal entity not named as a Party to this action. 12 2.10 Outside Counsel of Record: attorneys who are not employees of a party 13 to this Action but are retained to represent or advise a party to this 14 Action and have appeared in this Action on behalf of that party or are 15 affiliated with a law firm which has appeared on behalf of that party, 16 and includes support staff. 17 2.11 Party: any party to this Action, including all of its officers, directors, 18 employees, consultants, retained experts, and Outside Counsel of 19 Record (and their support staffs). 20 2.12 Privileged Information: any materials that contain information 21 protected from disclosure as defined by the Federal Rules of Civil 22 Procedure and/or the Federal Rules of Evidence. 23 2.13 Producing Party: a Party or Non-Party that produces Disclosure or 24 Discovery Material in this Action. 25 2.14 Professional Vendors: persons or entities that provide litigation support 26 services (e.g., photocopying, videotaping, translating, preparing 27 exhibits or demonstrations, and organizing, storing, or retrieving data 1 in any form or medium) and their employees and subcontractors. 2 2.15 Protected Material: any Disclosure or Discovery Material that is 3 designated as “CONFIDENTIAL.” 4 2.16 Receiving Party: a Party that receives Disclosure or Discovery Material 5 from a Producing Party. 6 7 3.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Jinna E. Miller v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jinna-e-miller-v-abbott-laboratories-cacd-2023.